Adam Durbin

Clinician-scientist Pediatric Oncologist focusing on chemical epigenetics & transcriptional circuitries. Better treatments, less toxicity. @stjuderesearch

[Adam Durbin @ADurbinLab]

Amazing new mechanistic insight bridging dna repair to Epigenetics! @ongnghiem and @LabHalic!

[St. Jude Research @StJudeResearch]

St. Jude scientists identified a direct role for PARP1 in chromatin remodeling, revealing for the first time how the protein partially disassembles nucleosomes to make damaged DNA accessible for repair. The findings could lead to more targeted PARP1 inhibitors and potentially reduce treatment toxicity. https://t.co/YWh6PuqrsW

[hai dao @ongnghiem]

Excited to share that our work is now published in Molecular Cell! We provide the first direct evidence for a role of hexasomes in DNA repair! Wonderful collaboration with @LabHalic, the Shelat labs, and St. Jude Imaging. https://t.co/TDbM38WDSJ

[Adam Durbin @ADurbinLab]

@masonbgrant @JExpMed Thank you for your message! We don't know formally because we didn't test fibrolamellar HCC cells, but it could be. If interested to chat more DM me!

[Adam Durbin @ADurbinLab]

Online today in @JExpMed,
https://t.co/EztTFMSnLX
TLDR: a genetically-defined group of osteosarcoma is sensitive to the EP300 PROTAC JQAD1, due to a balance between degradation and resynthesis by the ribosome. Read on for deets...

[Adam Durbin @ADurbinLab]

So excited to work with @JunQiLab on this important study!

[Dana-Farber News @DanaFarberNews]

New research published in @JExpMed from @DanaFarber’s @JunQiLab and collaborators reveals that AKT inhibitors synergize with EP300 degraders to suppress osteosarcoma growth in vitro and in vivo. These agents positively combine across cancer cells in a manner dependent on control of protein synthesis.

➡️https://t.co/Xtiwt65P4T

[St. Jude Research @StJudeResearch]

Researchers identified a potential therapeutic vulnerability in a subset of osteosarcoma. In preclinical models, combining EP300 degradation with AKT inhibition slowed tumor growth and prolonged survival. The findings suggest a potential path toward more personalized treatment. https://t.co/mti5ctijzY

[Adam Durbin @ADurbinLab]

We are grateful to the funders of this work for their support: @theNCI @NIH @StJudeResearch @StJude @hopeonwheels @CureSearch @RallyFoundation @ALSFNews @TheVFoundation @curingcancer and the Pediatric Dependencies Accelerator.

[Adam Durbin @ADurbinLab]

This work sets the stage for future work testing more drug-like EP300 degraders with AKT inhibitors in osteosarcoma and indeed, across many, many other types of cancer.

[Adam Durbin @ADurbinLab]

Competitive candidates have a computational background, as described in the application post below.

Come join us and make a difference!

https://t.co/E2jqsnbknP

@TheAbraLab @StJudeResearch @MolOnc_StJude

[Adam Durbin @ADurbinLab]

Looking for a post-doctoral fellowship in computational biology, focused on answering important questions in childhood cancer? Why wait? Apply now!

This position bridges the brilliant Brian J. Abraham lab computation with experimentation in the Adam Durbin lab @StJudeResearch.

[Adam Durbin @ADurbinLab]

@theNCI @RallyFoundation @ALSFNews @DamonRunyon @thesgconline @StJudeResearch @MolOnc_StJude

[Adam Durbin @ADurbinLab]

How “specific” are the inhibitors we use? In @nchembio, Sterling and Holtsmark et al reveal a dual inhibitory role for the clinical agent zavondemstat! Findings with implications for target and patient selection in trials, discussed by Drs Ali Nezhady and McKay-Corkum.

[Adam Durbin @ADurbinLab]

And our commentary here:

https://t.co/zqXCB3d0AL

This perhaps explains some of the exceptional activity in #neuroblastoma. @theNCI @RallyFoundation @ALSFNews @DamonRunyon @thesgconline